Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn C Matthews

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Alzheimer'S Disease : JAD|March 13, 2013
Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementiaLisa Mosconi, Randolph D Andrews, Dawn C Matthews
Alzheimer'S & Dementia (New York, N. Y.)|July 18, 2022
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifierDawn C Matthews, Ana S Lukic, Randolph D Andrews, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2019
Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)Michael S Rafii, Michael C Donohue, Dawn C Matthews, et al.
Current Alzheimer Research|June 17, 2014
An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's diseaseRaj C Shah, Dawn C Matthews, Randolph D Andrews, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 21, 2022
Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomesAdam C Raikes, Gerson D Hernandez, Dawn C Matthews, et al.
BMJ Open|November 28, 2018
Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City areaMichelle J Walters, Joanna Sterling, Crystal Quinn, et al.
Advances in Molecular Imaging|January 20, 2015
Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging StudyDawn C Matthews, Michelle Davies, John Murray, et al.
Neuroimage. Clinical|September 7, 2018
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage diseaseDawn C Matthews, Hedva Lerman, Ana Lukic, et al.
BMJ Open|March 26, 2018
Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City areaLisa Mosconi, Michelle Walters, Joanna Sterling, et al.
Journal of Alzheimer'S Disease : JAD|September 27, 2017
PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)Michael S Rafii, Ana S Lukic, Randolph D Andrews, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Alzheimer'S Disease : JAD|March 13, 2013
Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementiaLisa Mosconi, Randolph D Andrews, Dawn C Matthews
Alzheimer'S & Dementia (New York, N. Y.)|July 18, 2022
Measurement of neurodegeneration using a multivariate early frame amyloid PET classifierDawn C Matthews, Ana S Lukic, Randolph D Andrews, et al.
Journal of Alzheimer'S Disease : JAD|June 4, 2019
Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)Michael S Rafii, Michael C Donohue, Dawn C Matthews, et al.
Current Alzheimer Research|June 17, 2014
An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's diseaseRaj C Shah, Dawn C Matthews, Randolph D Andrews, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 21, 2022
Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomesAdam C Raikes, Gerson D Hernandez, Dawn C Matthews, et al.
BMJ Open|November 28, 2018
Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City areaMichelle J Walters, Joanna Sterling, Crystal Quinn, et al.
Advances in Molecular Imaging|January 20, 2015
Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging StudyDawn C Matthews, Michelle Davies, John Murray, et al.
Neuroimage. Clinical|September 7, 2018
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage diseaseDawn C Matthews, Hedva Lerman, Ana Lukic, et al.
BMJ Open|March 26, 2018
Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City areaLisa Mosconi, Michelle Walters, Joanna Sterling, et al.
Journal of Alzheimer'S Disease : JAD|September 27, 2017
PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)Michael S Rafii, Ana S Lukic, Randolph D Andrews, et al.
Pageof 3